Our findings suggest that combining the small molecule PIK-93 with monoclonal antibody–based ICIs can promote a favorable TME that enables enhanced efficacy of PD-1/PD-L1–mediated immunotherapy in lung cancer. Here, CD274 is linked to lung carcinoma.